# The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes

> **NCT06318442** · NA · RECRUITING · sponsor: **Imperial College London** · enrollment: 60 (estimated)

## Conditions studied

- Steroid-Induced Diabetes
- Steroid Induced Hyperglycemia

## Interventions

- **DRUG:** Semaglutide Oral Product
- **DRUG:** Metformin Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06318442
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318442, "The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06318442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*